Management of Recurrent Preterm Labor in Twin Gestations with Nifedipine Tocolysis

 

 Buy Article Permissions and Reprints

ABSTRACT

We examined outcomes of twin pregnancies complicated by recurrent preterm labor receiving nifedipine tocolysis. In a retrospective study design, twin pregnancies receiving outpatient preterm labor surveillance services and oral nifedipine tocolysis following a diagnosis of preterm labor were identified from a database (n = 1421). Eligible for inclusion were patients subsequently rehospitalized with recurrent preterm labor symptoms (n = 862). Included were patients at < 35 weeks' gestation, having intact membranes, and remaining undelivered for > 48 hours after recurrent preterm labor (n = 656). Pregnancy outcomes of women resuming nifedipine tocolysis (n = 418) following hospitalization were compared with those having an alteration in treatment (n = 238) to continuous subcutaneous terbutaline. Alteration of tocolytic treatment versus resuming nifedipine resulted in increased pregnancy prolongation (34.7 ± 18.8 days versus 27.5 ± 19.9 days, p < 0.001), with delivery of fewer low birth weight (67.2% versus 78.3%, p < 0.001) and very low birth weight infants (6.5% versus 15.0%, p < 0.001) and a decreased incidence of neonatal intensive care unit admission (44.7% versus 52.9%, p = 0.005). In twin pregnancies receiving nifedipine tocolysis, alteration of tocolytic treatment to subcutaneous terbutaline following hospitalization for recurrent preterm labor symptoms had a positive impact on pregnancy prolongation and neonatal outcomes.

REFERENCES

• 1 Martin J A, Hamilton B E, Sutton P D et al.. Births: Final Data for 2004. National Vital Statistics Reports, vol. 55, no. 1. Hyattsville, MD; National Center for Health Statistics 2006
  Google Scholar
• 2 Norwitz E R, Bahtiyar M O, Sibai B M. Defining standards of care in maternal-fetal medicine.  Am J Obstet Gynecol. 2004;  191 1491-1496
  CrossrefPubMedGoogle Scholar
• 3 Carr D B, Clark A L, Kernek K, Spinnato J A. Maintenance oral nifedipine for preterm labor: a randomized clinical trial.  Am J Obstet Gynecol. 1999;  181 822-827
  CrossrefPubMedGoogle Scholar
• 4 How H Y, Zafaranchi L, Stella C L et al.. Tocolysis in women with preterm labor between 32 0/7 and 34 6/7 weeks of gestation: a randomized controlled pilot study.  Am J Obstet Gynecol. 2006;  194 976-981
  CrossrefPubMedGoogle Scholar
• 5 Sayin N C, Varol F G, Baikanli-Kaplan P, Sayin M. Oral nifedipine maintenance therapy after acute intravenous tocolysis in preterm labor.  J Perinat Med. 2004;  32 220-224
  CrossrefPubMedGoogle Scholar
• 6 Pryde P G, Besinger R E, Gianopoulos J G, Mittendorf R. Adverse and beneficial effects of tocolytic therapy.  Semin Perinatol. 2001;  25 316-340
  CrossrefPubMedGoogle Scholar
• 7 Tsatsaris V, Papatsonis D, Goffinet F, Dekker G, Carbonne B. Tocolysis with nifedipine or beta-adrenergic agonists: a meta-analysis.  Obstet Gynecol. 2001;  97 840-847
  CrossrefPubMedGoogle Scholar
• 8 Kim A, Shim J-Y. Emerging tocolytics for maintenance therapy of preterm labour: oxytocin antagonists and calcium channel blockers.  BJOG. 2006;  113 113-115
  PubMedGoogle Scholar
• 9 van Geijn H P, Lenglet J E, Bolte A C. Nifedipine trials: effectiveness and safety aspects.  Br J Obstet Gynaecol. 2005;  112S 79-83
  PubMedGoogle Scholar
• 10 Oei S G. Calcium channel blockers for tocolysis: a review of their role and safety following reports of serious adverse events.  Eur J Obstet Gynecol Reprod Biol. 2006;  126 137-145
  CrossrefPubMedGoogle Scholar
• 11 Pryde P G, Janeczek S, Mittendorf R. Risk-benefit effects of tocolytic therapy.  Expert Opin Drug Saf. 2004;  3 639-654
  CrossrefPubMedGoogle Scholar
• 12 Lam F, Gill P, Smith M, Kitzmiller J L, Katz M. Use of subcutaneous terbutaline pump for long-term tocolysis.  Obstet Gynecol. 1988;  72 810-813
  PubMedGoogle Scholar
• 13 Fleming A, Bonebrake R, Istwan N, Rhea D, Coleman S, Stanziano G. Pregnancy and economic outcomes in patients treated for recurrent preterm labor.  J Perinatol. 2004;  24 223-227
  CrossrefPubMedGoogle Scholar
• 14 Lam F, Bergauer N K, Coleman S K, Stanziano G J, Jacques D. A comparison of gestational days gained with oral terbutaline versus continuous subcutaneous terbutaline in women with twin gestations.  J Perinatol. 2000;  20 408-413
  CrossrefPubMedGoogle Scholar
• 15 Lam F, Bergauer N K, Jacques D, Coleman S K, Stanziano G J. Clinical and cost-effectiveness of continuous subcutaneous terbutaline versus oral tocolytics for treatment of recurrent preterm labor in twin gestations.  J Perinatol. 2001;  21 444-450
  CrossrefPubMedGoogle Scholar
• 16 Morrison J C, Chauhan S P, Carrol Sr C S, Bofill J A, Magann E F. Continuous subcutaneous terbutaline administration prolongs pregnancy after recurrent preterm labor.  Am J Obstet Gynecol. 2003;  188 1460-1467
  CrossrefPubMedGoogle Scholar
• 17 Elliott J P, Istwan N B, Rhea D, Stanziano G. The occurrence of adverse events in women receiving continuous subcutaneous terbutaline therapy.  Am J Obstet Gynecol. 2004;  191 1277-1282
  CrossrefPubMedGoogle Scholar
• 18 Hill W C. Risks and complications of tocolysis.  Clin Obstet Gynecol. 1995;  38 725-745
  CrossrefPubMedGoogle Scholar
• 19 Abenhaim H A, Tremblay V, Trembly L, Audibert F. Feasibility of a randomized controlled trial testing nifedipine vs. placebo for the treatment of preterm labor.  J Perinat Med. 2007;  35 301-304
  CrossrefPubMedGoogle Scholar

Victor Hugo González-QuinteroM.D. M.P.H. 

University of Miami, Department of Obstetrics and Gynecology Maternal-Fetal Medicine

P.O. Box 016960 (R-136), Miami, Florida 33101

Email: vhgonzalez@med.miami.edu